The WHO released its first global guideline recommending GLP-1 drugs for the long-term treatment of obesity in adults, alongside intensive lifestyle support. Benefit: This landmark recognition elevates obesity to a chronic, treatable disease requiring lifelong care, potentially reducing global health costs associated with obesity-related illnesses like heart disease and diabetes, and improving access.